Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Generalized Pustular Psoriasis: Using AI for Rare Dermatologic Disease

Description

Marta Van Beek presents a project focused on Generalized Pustular Psoriasis (GPP), emphasizing the collaboration with OM1 and Data Derm over an 18-month period. The discussion highlights the vast data set from Data Derm, which includes over 60 million visits and 16 million patients, showcasing its utility in advocacy, quality reporting, and research. The presentation outlines the need for better diagnosis and understanding of GPP, a rare but severe condition often misdiagnosed, leading to prolonged suffering for patients. Recent advancements, such as new effective treatments like spizolimab, underscore the urgency for early identification of GPP patients. The analysis leverages real-world data to identify undiagnosed patients through a tool called Patient Finder, aimed at recognizing individuals who display symptoms or patterns indicative of GPP. Findings reveal that undiagnosed patients often experience significant comorbidities, including mental health issues, compared to diagnosed patients. The project aspires to educate healthcare providers on the typical patient journey and symptoms to enhance early intervention. Overall, the collaboration seeks to improve patient outcomes by ensuring timely and accurate diagnoses and providing appropriate treatment solutions.

View more

Conclusions

  • Generalized pustular psoriasis (GPP) is often underdiagnosed and misdiagnosed, leading to substantial delays in treatment and a significant impact on patients' quality of life.
  • The implementation of augmented intelligence and real-world data analysis can enhance the identification of undiagnosed GPP patients, potentially reducing the time to appropriate treatment.
  • The accuracy of AI models for identifying GPP patients depends heavily on the quality and integrity of the data used for training.
  • New treatment options, such as the IL-36 receptor antagonist Spesolimab, show effectiveness in providing relief from symptoms and improving patient outcomes.
  • The study emphasizes the importance of recognizing comorbidities associated with GPP, which differ between diagnosed and undiagnosed patients, to improve treatment strategies.
  • Awareness and educational initiatives targeting both patients and healthcare providers are crucial for enhancing the diagnosis and treatment of GPP.
  • American Journal of Clinical Dermatology (2022) 23 (Suppl 1):S21-S29 https://doi.org/10.1007/s40257-021-00654-z
  • Experimental Dermatology WILEY American Journal of Clinical Dermatology (2022) 23 (Suppl 1):S21-S29 https://doi.org/10.1007/s40257-021-00654-z
  • Strober B, et al. Dermatol Ther (Heidelb). 2021;11(2):529-41
  • Ericson, Oskar et al. JAAD, Volume 89, Issue 3, 616 - 619.
  • Lancet. 2023 Sep 19:S0140-6736(23)01378-8.